(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 12.6% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Alpha Teknova's revenue in 2026 is $41,802,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,396,600,666, with the lowest TKNO revenue forecast at $2,259,295,140, and the highest TKNO revenue forecast at $2,527,633,350. On average, 8 Wall Street analysts forecast TKNO's revenue for 2027 to be $2,750,131,566, with the lowest TKNO revenue forecast at $2,469,462,130, and the highest TKNO revenue forecast at $2,955,473,294.
In 2028, TKNO is forecast to generate $3,237,697,537 in revenue, with the lowest revenue forecast at $3,068,438,050 and the highest revenue forecast at $3,378,166,290.